TLPH — Talphera Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$1.18
-$0.01 (-0.84%)
Talphera Inc. (TLPH) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Vincent J. Angotti, based in 1850 Gateway Drive, San Mateo, CA, United States, 94404, with about 12 employees. Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Net income was -$4.4M. TLPH currently screens at market cap $50.3M.
Use this TLPH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TLPH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TLPH SEC filings page. Lician reads the product cache first so this HTML stays unique to Talphera Inc. even when a live quote feed is slow.
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
TLPH Key Statistics
Market Cap
$50.35M
Volume
318,437
Previous Close
$1.19
Day Range
$1.18 – $1.25
P/B Ratio
2.72
EPS
$0.00
Revenue
$0.00
Net Income
-$13.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
12
TLPH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$13.00M | -$18.40M | $47.76M |
| EPS (Diluted) | $0.00 | -$1.29 | $5.72 |
Total Assets
$18.24M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$8.86M
Operating Cash Flow
-$12.68M
Free Cash Flow
$0.00
Talphera Inc. Company Information
- CEO & Director
- Vincent J. Angotti
- Headquarters
- 1850 Gateway Drive, San Mateo, CA, United States, 94404
- Website
- talphera.com
- Phone
- 650 216 3500
- IPO / Founded
- 2011-02-11
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic